Cancer is a complex entity which encompasses a broad spectrum of unique pathologies that share the following hallmarks: Immune system evasion, tumor-promoting inflammation, genome instability, enabling replicative immortality, activating invasion and metastasis sustaining proliferative signaling, evading growth suppressors, resisting cell death, inducing angiogenesis, and metabolic reprogramming . Tumor-hypoxia plays a central role in many of these carcinogenic features, promoting an aggressive phenotype besides limit the effectiveness of radiotherapy, chemotherapy, and immunotherapy thereby worsening prognosis in the oncological patients . Thus, targeting tumoral hypoxia and its downstream effectors have been proposed as a potential therapeutical approach in cancer management. In this line, accumulating evidence supports the role of HBOT in the inhibition of tumor growth and therapy success, by three main mechanisms:
- By limiting cancer-associated hypoxia,
- Through the generation of ROS and RNS (Reactive oxygen and nitrogen species)
- Restoring immune function.
Actual investigations show the promising role of HBOT in a wide variety of malignancies, including breast cancer, prostate cancer, head and neck cancer, colorectal cancer, leukemia, brain tumors, cervical cancer and bladder cancer. Main applications derived from HBOT in oncology may be part of the treatment in both radiotherapy and chemotherapy applications.
Please book a consultation with us today, to see how HBOT can benefit your health.
